According to the TechSci Research report titled “India Human Papillomavirus Vaccine Market – By Region, Competition, Forecast, and Opportunities, 2029,” the human papillomavirus vaccine market in India is poised to experience impressive growth during the forecast period. This growth can be attributed to the increasing adoption of multi-valent human papillomavirus vaccines.
Over the last few years, the India human papillomavirus vaccine market has witnessed significant growth, primarily due to the use of multi-valent human papillomavirus vaccines. These vaccines are designed to protect against multiple strains of human papillomavirus, offering greater protection compared to the bivalent vaccine that targets only two strains. Currently, the market offers the quadrivalent and nonvalent human papillomavirus vaccines, which protect against more strains, including those associated with a higher risk of cervical cancer.
The uptake of multi-valent human papillomavirus vaccines in India has been driven by several factors, including increased awareness of the risks of cervical cancer, improved access to healthcare services, and the availability of newer and more effective vaccines. This trend is expected to continue, contributing to the market’s growth in the future. Key trends in the market include public-private partnerships, which aim to develop and distribute HPV vaccines in India, fostering innovation, cost reduction, and improved accessibility.
Various stakeholders, including governments, NGOs, and healthcare organizations, are working together to enhance access to HPV vaccines, particularly in rural areas with limited healthcare infrastructure. Initiatives such as mobile clinics, awareness campaigns, and subsidized vaccine programs are being implemented to increase vaccination rates.
Despite the positive growth trajectory, the reluctance of some patients toward vaccination poses a significant challenge to the human papillomavirus vaccine market in India. Concerns about safety, efficacy, and potential side effects are among the reasons behind this hesitation.
Browse over XX market data Figures spread through XX Pages and an in-depth TOC on the “India Human Papillomavirus Vaccine Market” – https://www.techsciresearch.com/report/india-human-papillomavirus-vaccine-market/15602.html
The India human papillomavirus vaccine market can be further segmented based on valence, disease indication, distribution channel, and region:
– Disease Indication: The market is segmented into cervical cancer, anal cancer, vaginal cancer, penile cancer, vulvar cancer, and others. Cervical cancer dominates this segment, as it is the most common human papillomavirus-related cancer in India. The use of HPV vaccines has the potential to significantly reduce cervical cancer incidence.
– Distribution Channel: The market can be segmented into online markets and others. Online markets are expected to dominate during the forecast period, driven by the increasing use of digital technology in healthcare. Patients are turning to e-commerce platforms to access HPV vaccines, diagnostic tests, and treatments, especially in remote or underserved areas.
Moreover, the COVID-19 pandemic has further accelerated the growth of online markets in the healthcare sector, including the human papillomavirus vaccine market. Social distancing measures and lockdowns have prompted patients to seek healthcare products and services through online platforms for convenience and accessibility.
Major companies operating in the India Human Papillomavirus Market are:
- Bharat Biotech International Ltd.
- GlaxoSmithKline Pharmaceuticals Limited
- MSD Pharmaceuticals Private Limited
- Serum Institute of India Pvt. Ltd.
- HLL Lifecare Limited
- Panacea Biotec Ltd.
Recent Development
- In 2020, MSD entered into a collaboration with Indian Immunological Limited (IIL) to expand access to Gardasil 9, a multi-valent HPV vaccine, in India. Under the collaboration, IIL will distribute the vaccine in India.
- In 2019, Panacea Biotec announced a collaboration with SII to develop and manufacture a quadrivalent HPV vaccine. The vaccine is currently in clinical trials.
Customers can also request 10% free customization on this report.
“The India human papillomavirus vaccine market is expected to gain substantially from the rising in cancer cases caused by Papillomavirus, such as vulva cancer, vagina cancer, oropharynx cancer (back of throat including base of tongue and tonsils). Furthermore, this market is in its nascent stage and is expected to experience significant growth in the coming years. The inclusion of human papillomavirus vaccines in the national immunization program and the increasing awareness about cervical cancer prevention are likely to play an important role in driving the growth in this market. Besides, rising concerns about healthy lifestyles and increasing expenditure on health and wellness are further expected to create lucrative opportunities for the market’s growth over the forecast period,” said Mr. Karan Chechi, Research Director at TechSci Research, a research-based global management consulting firm.
India Human Papillomavirus Vaccine Market By Valence (Bivalent, Quadrivalent, Nonvalent, and Others), By Disease Indication (Cervical Cancer, Anal Cancer, Vaginal Cancer, Penile Cancer, Vulvar Cancer, and Others), By Distribution Channel (Hospitals & Clinics, Governmental & Non-Governmental Organizations, Public & Private Alliances, and Others), and By Region and Competition, Forecast & Opportunities, 2029 has evaluated the future growth potential of the India human papillomavirus vaccine market and provides statistics & information on market size, structure, and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in the India human papillomavirus vaccine market.
Download Free Sample Report – https://www.techsciresearch.com/sample-report.aspx?cid=15602
About TechSci Research:
TechSci Research is a research-based management consulting firm providing market research and advisory solutions to its customers worldwide, spanning a range of industries. TechSci Research’s core values are value, integrity and insight. Led by a team of dynamic industry experts, TechSci Research provides its customers with high value market research and advisory services that helps them identify new market opportunities, growth engines and innovative ways to capture the market share. As a result, TechSci’s client leads rather than follow market trends. Not bound by legacy, TechSci’s cutting-edge research model leverages its decades of research knowledge and increased use of technology as engines of innovation to deliver unique research value. Provided as an alternative to traditional market research, TechSci Research reports do not just deliver data and knowledge rather highlights the insights in a more usable and interactive format for its clients.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: [email protected]
Web: https://www.techsciresearch.com
